Clinical and genetic characterization of patientswith BCR::ABL1 and JAK2 V617F

被引：0
|
作者：
Dangelo, V. [1 ]
Schwaab, J. [1 ]
Luebke, J. [1 ]
Fabarius, A. [1 ]
Hagen, V. [2 ]
Horing, E. [3 ]
Dengler, J. [4 ]
Metzgeroth, G. [1 ]
Kreil, S. [1 ]
Hofmann, W. K. [1 ]
Saussele, S. [1 ]
Reiter, A. [1 ]
Naumann, N. [1 ]
机构：
[1] Heidelberg Univ, Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany
[2] St Johannes Hosp Dortmund, Klin Innere Med II, Dortmund, Germany
[3] Onkologikum Stuttgart, Stuttgart, Germany
[4] Onkolog Schwerpunktpraxis Heilbronn, Heilbronn, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V893
引用
收藏
页码：266 / 266
页数：1
相关论文
共 50 条
  • [1] BCR::ABL1 translocation and JAK2 V617F mutation testing in myeloproliferative neoplasms
    Paro, M. M. Kardum
    Svabek, Z. Tkalcic
    Horvat, M.
    Martinovic, M.
    Smoljanovic, I. Mandac
    Kolonic, S. Ostojic
    Kristo, D. Radic
    CLINICA CHIMICA ACTA, 2024, 558
  • [2] Concomitant BCR ABL Translocation and JAK2 V617F Mutation in Myeloproliferative Disorders
    Hummel, J. M.
    Sanks, J.
    Chiselite, M.
    Smith, L. B.
    Johnson, K. Elenitoba
    Lim, M. S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (06): : 869 - 869
  • [3] MOLECULAR CHARACTERIZATION OF MYELOPROLIFERATIVE NEOPLASMS WITH CONCOMITANT BCR-ABL1 AND JAK2 V617F OR CALRETICULIN MUTATIONS
    Bodor, C.
    Kiraly, P.
    Krahling, T.
    Gango, A.
    Marosvari, D.
    Masszi, T.
    Fekete, S.
    Ujj, G.
    Egyed, M.
    Farkas, P.
    Csomor, J.
    Kajtar, B.
    Bors, A.
    Tordai, A.
    Andrikovics, H.
    HAEMATOLOGICA, 2016, 101 : 551 - 551
  • [4] Myeloproliferative Neoplasms with Concurrent BCR-ABL1 Translocation and JAK2 V617F Mutation
    Soderquist, Craig
    Ewalt, Mark D.
    Czuchlewski, David
    Geyer, Julia
    Rogers, Heesun J.
    Babushok, Daria
    Hexner, Elizabeth
    Orazi, Attilio
    Hsi, Eric D.
    Wang, Sa
    Bueso-Ramos, Carlos E.
    Arber, Daniel A.
    Bagg, Adam
    LABORATORY INVESTIGATION, 2016, 96 : 377A - 377A
  • [5] CASE REPORT OF CONCURRENT JAK2 V617F MUTATION AND BCR/ABL1 TRANSLOCATION WITH NEXT-GENERATION SEQUENCING STUDY
    Jiang, Xiu Yan
    Savoie, Lynn
    Sinclair, Gary
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 : 48 - 49
  • [6] Myeloproliferative Neoplasms with Concurrent BCR-ABL1 Translocation and JAK2 V617F Mutation
    Soderquist, Craig
    Ewalt, Mark D.
    Czuchlewski, David
    Geyer, Julia
    Rogers, Heesun J.
    Babushok, Dania
    Hexner, Elizabeth
    Orazi, Attilio
    Hsi, Eric D.
    Wang, Sa
    Bueso-Ramos, Carlos E.
    Arber, Daniel A.
    Bagg, Adam
    MODERN PATHOLOGY, 2016, 29 : 377A - 377A
  • [7] CBC THRESHOLDS REDUCE UNNECESSARY JAK2 V617F AND BCR-ABL1 TESTING
    Eaton, Alex
    Gillan, Tanya
    Conrad, David
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 58 - 58
  • [8] SUPPRESSOR OF CYTOKINE SIGNALING 3 IS DOWN-REGULATED BY BCR-ABL AND RESULTS IN LOSS OF JAK2 V617F IN A PATIENT WITH CONCURRENT BCR-ABL TRANSLOCATION AND JAK2 V617F MUTATION
    Ang, C. H.
    Gan, G. G.
    Nadarajan, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 402 - 403
  • [9] JAK2 V617F Genetic Biomarker Used in Differential Diagnosis for BCR-ABL1 Negative Myeloproliferative Neoplasms
    Talmaci, Rodica
    Cucu, Natalia
    Dragomir, Mihaela
    Aposteanu, Silvia
    Coriu, D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S356 - S357
  • [10] A Rare Entity in Chronic Myelocytic Leukemia: Coexistence of BCR ABL1 Translocation and JAK2 V617F Mutation. Case Report
    Buğra Sağlam
    Murat Albayrak
    Abdulkerim Yıldız
    Pınar Akyol
    Çiğdem Pala Öztürk
    Senem Maral
    Hacer Berna Afacan Öztürk
    Mesut Tığlıoğlu
    Osman Şahin
    SN Comprehensive Clinical Medicine, 2020, 2 (4) : 478 - 480
12345